Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
First Claim
Patent Images
1. A pharmaceutical composition in unit dosage form that comprises:
- a therapeutically effective amount of a levothyroxine sodium;
an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation;
an amount of an alditol sufficient to stabilize the levothyroxine sodium; and
at least two excipients selected from the group consisting of a filler, a binder, and a lubricant, wherein;
the alditol is at least one member selected from the group consisting of a mannitol, a sorbitol, a maltitol, and a xylitol;
the composition is free of added saccharide selected from the group consisting of a monosaccharide, a disaccharide, and an oligosaccharide; and
the composition is storage stable.
2 Assignments
0 Petitions
Accused Products
Abstract
Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of an alditol sufficient to stabilize the levothyroxine sodium; and at least two excipients selected from a filler, a binder, and a lubricant. Such compositions are free of added monosaccharide, disaccharide, and an oligosaccharide and are storage stable.
-
Citations
23 Claims
-
1. A pharmaceutical composition in unit dosage form that comprises:
- a therapeutically effective amount of a levothyroxine sodium;
an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation;
an amount of an alditol sufficient to stabilize the levothyroxine sodium; and
at least two excipients selected from the group consisting of a filler, a binder, and a lubricant, wherein;the alditol is at least one member selected from the group consisting of a mannitol, a sorbitol, a maltitol, and a xylitol; the composition is free of added saccharide selected from the group consisting of a monosaccharide, a disaccharide, and an oligosaccharide; and the composition is storage stable. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- a therapeutically effective amount of a levothyroxine sodium;
-
9. A pharmaceutical composition in unit dosage form that comprises:
- a levothyroxine sodium in one amount selected from the group consisting of 25 μ
g, 50 μ
g, 75 μ
g, 88 μ
g, 100 μ
g, 112 μ
g, 137 μ
g, 150 μ
g, 175 μ
g, 200 μ
g, and 300 μ
g;
1%-70% w/w of an alditol;
1%-80% w/w of a filler;
0.001%-10% w/w of a binder;
0.001%-5% w/w of an antioxidant;
0.1%-5% w/w of a glidant; and
0.001%-5% w/w of a surfactant, wherein the composition is free of added saccharide selected from the group consisting of a monosaccharide, a disaccharide, and an oligosaccharide, and wherein the composition is storage stable. - View Dependent Claims (10, 11, 12, 13, 14, 15)
- a levothyroxine sodium in one amount selected from the group consisting of 25 μ
-
16. A pharmaceutical composition in unit dosage form that comprises:
- a levothyroxine sodium in one amount selected from the group consisting of 25 μ
g, 50 μ
g, 75 μ
g, 88 μ
g, 100 μ
g, 112 μ
g, 137 μ
g, 150 μ
g, 175 μ
g, 200 μ
g, and 300 μ
g;
20%-60% w/w of an alditol;
10%-70% w/w of a filler;
1%-5% w/w of a binder;
0.1%-1% w/w of an antioxidant;
0.1%-3% w/w of a glidant; and
0.01%-1% w/w of a surfactant, wherein the composition is free of added saccharide selected from the group consisting of a monosaccharide, a disaccharide, and an oligosaccharide, and wherein the composition is storage stable. - View Dependent Claims (17, 18, 19, 20, 21, 22)
- a levothyroxine sodium in one amount selected from the group consisting of 25 μ
-
23. A pharmaceutical composition in unit dosage form that comprises:
-
a levothyroxine sodium in one amount selected from the group consisting of 25 μ
g, 50 μ
g, 75 μ
g, 88 μ
g, 100 μ
g, 112 μ
g, 137 μ
g, 150 μ
g, 175 μ
g, 200 μ
g, and 300 μ
g;37.50%-42.50% w/w of a mannitol; 0.75%-1.50% w/w of a polyvinylpyrrolidone; 1.00%-2.00% w/w of a magnesium stearate; 52.50%-62.50% w/w of a microcrystalline cellulose, a dicalcium phosphate, or a combination of microcrystalline cellulose and dicalcium phosphate; 0.20%-1.00% w/w of a colloidal silicon dioxide; 30.00%-35.00% w/w of a dicalcium phosphate; 0.0075%-0.015% w/w of a butylated hydroxyanisole; and 0.075%-0.15% w/w of a sodium lauryl sulfate, and wherein the composition is free of added saccharide selected from the group consisting of a monosaccharide, a disaccharide, and an oligosaccharide, and wherein the composition is storage stable.
-
Specification